Frontiers in thoracic oncology: new breakthroughs in molecular targets and immunotherapy
In the FLAURA study, osimertinib achieved a median PFS of 18.9 months as a first‑line treatment for NSCLC patients with drug‑sensitive EGFR mutations, and the survival benefit was superior compared to that of first‑generation EGFR‑TKIs.
Thoracic tumors, including lung cancer, breast cancer, and thymoma, usually present poor outcomes. The current treatment methods for thoracic tumors have low efficacy and are associated with severe adverse reactions. Molecular targeted therapy and immunotherapy offer new possibilities for the treatment of thoracic tumors. In this review, we have summarized the latest research on these novel therapeutic strategies, and discussed their clinical applications, challenges, and possible countermeasures. This review offers a theoretical basis for improving the outcomes of thoracic tumor patients, along with future research prospects.
This finding demonstrates that third‑generation EGFR‑TKIs provide a clinically meaningful improvement in progression‑free survival over earlier generation agents, underscoring the importance of targeted therapy sequencing in patients with EGFR‑mutant non‑small‑cell lung cancer.
Bizonyítékszint: Sejtvonalas. Laboratóriumi sejtekben vizsgálták.
Kapcsolódó jelek
- Telisotuzumab Vedotin + Osimertinib for Non‑Small Cell Lung Cancer
- Ramucirumab plus erlotinib in patients with untreated, EGFR‑mutated, advanced non‑small‑cell lung cancer (RELAY): a randomised, double‑blind, placebo‑controlled, phase 3 trial
- Recent advancements in lung cancer research: a narrative review
- Advances in Non-Small Cell Lung Cancer: Current Insights and Future Directions
- Structured proxy features for multimodal NSCLC survival prediction from pretreatment CT